Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars

Michael Goettler Sets Out Vision For Viatris On Anniversary Of Mylan-Upjohn Merger

13 Dec 2021

As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.

Michael Goettler, Viatris CEO — Michael Goettler says Viatris is 'a new kind of healthcare company' • Source: Viatris

Speaking to Viatris CEO Michael Goettler on the first anniversary of the merger between Mylan and Upjohn, his enthusiasm for the firm’s achievements over the past 12 months is immediately obvious.

“It feels good to reflect a little bit on all that we have accomplished in the first year, because it’s...